Preferred Label : Noninvasive prenatal fetal aneuploidy panel:-:Pt:WBC.DNA Plas.cfDNA:-:Dosage of chromosome
specific cf DNA;
LOINC status : ACTIVE;
LOINC display name : Noninvasive prenatal fetal aneuploidy panel Dosage of chromosome-specific cfDNA (Plasma
cell-free WBC DNA);
LOINC long common name : Noninvasive prenatal fetal aneuploidy panel - Plasma cell-free WBC DNA by Dosage of
chromosome-specific cfDNA;
LOINC short name : NIP fet aneu Pnl WBC.DNA cfDNA;
LOINC description : This panel includes quantitative and qualitative risk terms for aneuploidies, including
trisomy 13, 18 and 21, monosomy X, and triploidy. Noninvasive prenatal screening is
used to assess fetal risk for various genetic conditions without requiring invasive
maternal procedures such as amniocentesis or chorionic villus sampling. Cell-free
DNA (cfDNA) in maternal plasma comes from both fetal and maternal sources, and depending
on the technology used, this DNA can be used to determine fetal risk for a variety
of conditions including aneuploidy (e.g., trisomy 21, monosomy X) and microdeletions
(e.g., 22q11.2 deletion). This panel was developed for, but is not limited in use
to, Natera's Panorama aneuploidy only prenatal test, which incorporates SNP analysis
of maternal white blood cell DNA with combined maternal and fetal cfDNA SNP analysis.
Natera's proprietary informatics analysis method (NATUS) effectively subtracts the
maternal genotype from the cfDNA genotype and analyzes the remaining fetal cfDNA genotype
for certain aneuploidies and microdeletion syndromes.;
Origin ID : 96977-4;
UMLS CUI : C5452117;
Has component
- Has method
- Has system
- Has time aspect
- Panel of LOINC codes
- Semantic type(s)
